Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | RNA Stock NewsStockTitan·Jul 20 at 08:58 AMRNA+1.73%
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)Tip Ranks·Jul 16 at 04:45 AMRNA+1.73%RANK-0.15%
Atrium Therapeutics gets FDA IND clearance for ATR 1072, Corventis Phase 1/2 trial to startTradingView·Jul 14 at 04:23 PMRNA+1.73%
Atrium Therapeutics publishes investor presentation on precision RNA medicines for cardiac diseasesPUBT·Jul 14 at 05:40 AMRNA+1.73%
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome | RNA Stock NewsStockTitan·Jul 13 at 09:30 PMRNA+1.73%
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Unusual Whales·Jun 23 at 03:07 PMRNA+1.73%
Atrium Therapeutics grants 8 new hires stock awards including 66,000 options at $12.66PUBT·Jun 23 at 03:05 PMRNA+1.73%
Atrium Therapeutics Reports First Quarter 2026 Financial Results | RNA Stock NewsStockTitan·May 14 at 07:40 AMRNA+1.73%
